These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 27814414)

  • 41. Oral PSORI-CM01, a Chinese herbal formula, plus topical sequential therapy for moderate-to-severe psoriasis vulgaris: pilot study for a double-blind, randomized, placebo-controlled trial.
    Yao DN; Lu CJ; Wen ZH; Yan YH; Xuan ML; Li XY; Li G; He ZH; Xie XL; Deng JW; Guo XF; Ou AH
    Trials; 2016 Mar; 17(1):140. PubMed ID: 26983642
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Methotrexate: understanding the risk in psoriasis patients.
    Lucas J; Ntuen E; Pearce DJ; Fleischer AB; Feldman SR
    J Dermatolog Treat; 2009; 20(5):311-3. PubMed ID: 19363738
    [No Abstract]   [Full Text] [Related]  

  • 43. Systemic treatment with fumaric acid esters in six paediatric patients with psoriasis in a psoriasis centre.
    Steinz K; Gerdes S; Domm S; Mrowietz U
    Dermatology; 2014; 229(3):199-204. PubMed ID: 25247273
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Small Molecules for Psoriasis.
    Leonardi CL
    Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S65-6. PubMed ID: 27525564
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety of ustekinumab in severe psoriasis with chronic hepatitis B.
    Raymundo AR; Facin AP; Silva de Castro CC; Faria AR
    Indian J Dermatol Venereol Leprol; 2016; 82(3):326-8. PubMed ID: 27088944
    [No Abstract]   [Full Text] [Related]  

  • 46. Use of infliximab in the treatment of psoriasis.
    Lee MR; Cooper AJ
    Australas J Dermatol; 2004 Aug; 45(3):193-5. PubMed ID: 15250904
    [No Abstract]   [Full Text] [Related]  

  • 47. Psoriasis and its treatment with infliximab-mediated tumor necrosis factor alpha blockade.
    Winterfield L; Menter A
    Dermatol Clin; 2004 Oct; 22(4):437-47, ix. PubMed ID: 15450339
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tacalcitol in the treatment of psoriasis vulgaris: the Spanish experience.
    Lecha M; Mirada A; López S; Artés M;
    J Eur Acad Dermatol Venereol; 2005 Jul; 19(4):414-7. PubMed ID: 15987284
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Topical therapies for localized psoriasis.
    Witman PM
    Mayo Clin Proc; 2001 Sep; 76(9):943-9. PubMed ID: 11560307
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment.
    Papp K; Leonardi C; Menter A; Thompson EH; Milmont CE; Kricorian G; Nirula A; Klekotka P
    J Am Acad Dermatol; 2014 Dec; 71(6):1183-1190.e3. PubMed ID: 25313095
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Medication Errors: A Case-Based Review.
    Pop M; Finocchi M
    AACN Adv Crit Care; 2016 Feb; 27(1):5-11. PubMed ID: 26909446
    [No Abstract]   [Full Text] [Related]  

  • 52. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).
    Paul C; Lacour JP; Tedremets L; Kreutzer K; Jazayeri S; Adams S; Guindon C; You R; Papavassilis C;
    J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1082-90. PubMed ID: 25243910
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Facial hair growth in a patient with psoriasis.
    Matos RS; Torres T
    Aust Fam Physician; 2016 Sep; 45(9):641-2. PubMed ID: 27606364
    [No Abstract]   [Full Text] [Related]  

  • 54. A randomized controlled trial of methotrexate and cyclosporine in the treatment of psoriasis.
    Bigby M
    Arch Dermatol; 2004 Mar; 140(3):347-8. PubMed ID: 15023778
    [No Abstract]   [Full Text] [Related]  

  • 55. The right dose in the right place: an overview of current prescription, instruction and application modalities for topical psoriasis treatments.
    Savary J; Ortonne JP; Aractingi S
    J Eur Acad Dermatol Venereol; 2005 Nov; 19 Suppl 3():14-7. PubMed ID: 16274407
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adult T-cell lymphoma/leukaemia developing in a patient with psoriasis treated with long-term cyclosporine.
    Watabe H; Soma Y; Obara W; Murakami N; Kawase A; Mizukami T; Koike M; Shibuya Y; Mizoguchi M
    Acta Derm Venereol; 2006; 86(2):184-5. PubMed ID: 16648935
    [No Abstract]   [Full Text] [Related]  

  • 57. Methotrexate versus hydroxycarbamide (hydroxyurea) as a weekly dose to treat moderate-to-severe chronic plaque psoriasis: a comparative study.
    Ranjan N; Sharma NL; Shanker V; Mahajan VK; Tegta GR
    J Dermatolog Treat; 2007; 18(5):295-300. PubMed ID: 17852635
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of biologics in the treatment of moderate-to-severe plaque psoriasis.
    Puig L
    G Ital Dermatol Venereol; 2017 Feb; 152(1):28-35. PubMed ID: 27627100
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
    Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: a randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting.
    van de Kerkhof PC; van der Valk PG; Swinkels OQ; Kucharekova M; de Rie MA; de Vries HJ; Damstra R; Oranje AP; de Waard-van der Spek FB; van Neer P; Lijnen RL; Kunkeler AC; van Hees C; Haertlein NG; Hol CW
    Br J Dermatol; 2006 Oct; 155(4):800-7. PubMed ID: 16965431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.